ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 2155 • ACR Convergence 2024

    Direct Comparison of Sleep Quality and Risk Factors for Poor Sleep Across Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis

    Dagna Polak1, Mateusz Wilk2, Piotr Kuszmiersz1, Glenn Haugeberg3, Mariusz Korkosz4 and Zofia Guła4, 1University Hospital in Cracow, Kraków, Poland, 2Univesity Hospital in Cracow, Kraków, Poland, 3Sørlandet Hospital, Kristiansand, Kristiansand, Norway, 4Department of Rheumatology and Immunology, Jagiellonian University Medical College, Kraków, Poland

    Background/Purpose: Sleep disorders are common among patients with inflammatory arthritis (IA) and have probably bilateral influence on disease activity and quality of life. Pathomechanism of…
  • Abstract Number: 2224 • ACR Convergence 2024

    Age of Onset of Rheumatoid Arthritis and Radiographic Changes

    Masaru Shimizu1, Misti Paudel2, Nancy Shadick3, Michael Weinblatt4 and Daniel Solomon5, 1University of Tsukuba, Yokohama, Kanagawa, Japan, 2Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Epidemiological studies have shown that the age of onset for rheumatoid arthritis (RA) is increasing. However, associations between age of onset and joint erosion…
  • Abstract Number: 2240 • ACR Convergence 2024

    Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis

    George Karpouzas1, Piet Van RIel2, Elena Myasoedova3, Miguel Angel Gonzalez-Gay4, alfonso Corrales-Martínez5, Solbritt Rantapaa-Dahlqvist6, Petros Sfikakis7, Patrick Dessein8, Linda Tsang9, Carol Hitchon10, Hani El Gabalawy11, Virginia Pascual Ramos12, Irazu Contreras Yanez13, Iris Jazmín Colunga Pedraza14, Dionicio Galarza-Delgado15, jose Ramon Azpiri-Lopez16, Anne Grete Semb17, Patrick Durez18, Durga P Misra19, Brian Bridal Logstrup20, Ellen Margrethe Hauge21, George Kitas22 and Sarah Ormseth23, and ATACC-RA, 1Harbor-UCLA Medical Center, Torrance, CA, 2Radboud University Medical Center, Nijmegen, Netherlands, 3Mayo Clinic, Rochester, MN, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Hospital Universitario Marques de Valdecilla, Santander, Spain, 6Umeå University, Umeå, Sweden, 7Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 8University of Witwatersrand, Johannesburg, South Africa, 9University of Witwatersrand, Johanessburg, South Africa, 10University of Mannitoba, Winnipeg, Canada, 11University of Mannitoba, Winnipeg, MB, Canada, 12Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, 13Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 14Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 15UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 16Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 17Diakonhjemmet Hospital, Oslo, Norway, 18UCLouvain, Louvain, Belgium, 19Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 20University of Aarhus, Aarhus, Denmark, 21Aarhus Universitetshospital, Aarhus, Denmark, 22The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, 23The Lundquist Institute, Torrance, CA

    Background/Purpose: Disease activity was linked to cardiovascular (CV) risk in rheumatoid arthritis (RA). Anticitrullinated protein antibody (ACPA) positivity associated with greater synovial inflammation, tumor necrosis…
  • Abstract Number: 2260 • ACR Convergence 2024

    Statin Use in Patients with Rheumatoid Arthritis (RA) and Osteoarthritis: Are RA Patients More Likely to Receive Statins?

    Axi Patel1, Pim Jetanalin2, WL Galanter1, Elaine Adams3 and HJ CHANG2, 1University of Illinois at Chicago; Jesse Brown VA Medical Center, CHICAGO, IL, 2RHEUMATOLOGIST, CHICAGO, IL, 3Jesse Brown VA Medical Center, La Grange, IL

    Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD) partly due to accelerated atherosclerosis from chronic inflammation. However, this increased risk…
  • Abstract Number: 2278 • ACR Convergence 2024

    Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study

    Olga Tsyruk1, Marina Birck2, Sasha Bernatsky2, Luck Lukusa3, Denis Choquette4, Gilles Boire5 and Walter Maksymowych6, 1McGill University, Montreal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4Rhumadata™, Montreal, QC, Canada, 5Retired, Sherbrooke, QC, Canada, 6University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Treatment adherence is crucial to optimizing outcomes in rheumatic diseases. Suboptimal adherence is common with inflammatory and chronic diseases, often treated with biologics, including…
  • Abstract Number: 2541 • ACR Convergence 2024

    Probiotic Modulation of Gut Microbiota Mitigates Early Rheumatoid Arthritis Progression: Insights from Pre-Clinical Models

    Tong Wu1, Yanhong Li2, Yubin Luo1 and Yi Liu3, 1West China Hospital, Sichuan University, Cheng Du, China (People's Republic), 2West China School of Medicine and West China Hospital, Sichuan University, Cheng Du, Sichuan, China, 3West China Hospital of Sichuan University, Chengdu, Sichuan, China

    Background/Purpose: Rheumatoid arthritis (RA) progression, categorized by EULAR into six stages, includes pre-clinical RA (Pre-RA)[1], where mucosal surfaces are implicated as initiators of autoimmune responses…
  • Abstract Number: 2664 • ACR Convergence 2024

    BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease

    Laura Bucci1, Melanie Hagen2, Sebastian Boeltz2, Danae-Mona Noethling2, Tobias Rothe2, Maria Gabriella Raimondo1, Carlo Tur1, Andreas Wirsching1, Jochen Wacker1, Aline Bozec1, Georg Schett3 and Ricardo Grieshaber-Bouyer2, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
  • Abstract Number: 0042 • ACR Convergence 2024

    Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model

    Eva Philippon1, Jan Piet van Hamburg1, Lisanne van Rooijen1, Gary Sims2, Conny Van der Laken3 and Sander Tas4, 1Amsterdam UMC, Amsterdam, Netherlands, 2Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 3Amsterdam UMC - location VUMC, Amsterdam, Netherlands, 4Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder characterized by chronic and destructive joint inflammation. Key features of RA include synovial cell…
  • Abstract Number: 0059 • ACR Convergence 2024

    Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance

    Susanna R. Bidgood1, Sophie Hopkin1, Kathryn R. Malpas1, David M. Kallenberg1, Jacqueline O’Neill1, Geofrey Odede1, Bernard Lauwerys2, Baran Ufuktepe3 and David Humphreys1, 1UCB Biopharma UK, Slough, United Kingdom, 2UCB Pharma, Brussels, Belgium, 3UCB Pharma, Istanbul, Turkey

    Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels have poorer prognosis, more severe progressive…
  • Abstract Number: 0144 • ACR Convergence 2024

    More Than a Monolith: Disaggregating Rheumatoid Arthritis Prevalence Among Asian American Subgroups

    John Chen1, Tanya Selvam1, Jeanne Darbinian2, Christopher Macko1, Nirmala Ramalingam2, Joan Lo2 and Lucy Liu2, 1Kaiser Permanente Oakland Medical Center, Oakland, CA, 2Kaiser Permanente, Oakland, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a disabling, autoimmune condition affecting up to as many as 17.6 million individuals worldwide. Epidemiologic evidence in the United States…
  • Abstract Number: 0227 • ACR Convergence 2024

    Active Hand Inflammation: Differing Clinical and Ultrasound Patterns in Patients with Rheumatoid Arthritis and Psoriatic Arthritis. A Cross-Sectional and Multicenter Study

    Julio Ramírez1, Vicenç Torrente-Segarra2, Andrea Cuervo3, Mireia Moreno4, Ana Belén Azuaga1, Lourdes Mateo5, Beatriz Frade-Sosa6, Andrea Zacarias1, Noemí Busquets Pérez7, Susana Holgado8, Paula Estrada-Alarcón9, Delia Reina10, Juan José De Agustín11, Carme Moragues12, María Bonet13, Sandra Farietta1, Patricia Corzo1, Andrés Ponce14, Virginia Ruiz Esquide1, Lucia Alascio1 and Juan Cañete15, and ECOCAT group, 1Hospital Clinic Barcelona, Barcelona, Spain, 2Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, 3Hospital General Granollers, Granollers, Spain, 4Hospital Parc Taulí, Sabadell, Spain, 5Hospital Germans Trias i Pujol, Badalona, Spain, 6Hospital Clínic, Barcelona, Spain, 7HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, 8Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 9Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, 10Hospital Moises Broggi, Barcelona, Spain, 11Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, 12Hospital Bellvitge, Barcelona, Spain, 13Hospital Alt Penedés i Garraf, Barcelona, Spain, 14Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 15Hospital Clinic an IDIBAPS, Barcelona, Spain

    Background/Purpose: The ultrasound (US) finding of proliferative synovitis (PS) in Rheumatoid Arthritis (RA), is associated with ACPA, erosions and changes in therapy [1]. However, no…
  • Abstract Number: 0369 • ACR Convergence 2024

    Can Treatment Expectations or Treatment Itself in Patients with Arthralgia Suspicious for Progression to Rheumatoid Arthritis Improve Illness Perceptions?

    Simonetta van Griethuysen1, Quirine Dumoulin2 and Annette van der Helm-van Mil3, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 3LUMC, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: Negative Illness perceptions (IPs) are associated with poorer disease outcomes in  rheumatoid arthritis (RA). Unfortunately, IPs are generally fixed in established RA. We hypothesized…
  • Abstract Number: 0463 • ACR Convergence 2024

    Evaluation of Inflammatory Indices as Predictive Biomarkers of Carotid Plaque in Patients with Rheumatoid Arthritis

    Jose Antonio Davila Jimenez1, Dionicio Galarza-Delgado2, Iris Jazmín Colunga Pedraza3, jose Ramon Azpiri-Lopez4, Rosa Icela Arvizu-Rivera3, Jesus Cardenas-de la Garza5, Aleydis Gonzalez Melendez3, Andrea Guajardo Aldaco3, Maria F. Elizondo-Benitez6, Rebeca L. Polina-Lugo3 and Diego Salcedo-Almanza7, 1Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 2UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 5Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 6Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 7Division of Radiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk compared to the general population. All stages of the atherogenic process appear to…
  • Abstract Number: 0479 • ACR Convergence 2024

    Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis

    Shant Ayanian, Collin Osborne, Marc Blasi, Daniel Darveaux, Eric Klee and Elena Myasoedova, Mayo Clinic, Rochester, MN

    Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…
  • Abstract Number: 0497 • ACR Convergence 2024

    Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis

    Adrián Quevedo-Rodríguez1, Marta Hernández-Díaz2, Dara Rodríguez-González22, Fuensanta Gomez-Bernal3, Juan Carlos Quevedo-Abeledo4, Agustín F González-Rivero2, Elena González López5, gonzalo Ocejo-Viñals5, Miguel Angel Gonzalez-Gay6 and ivan Ferraz-Amaro7, 1Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 2Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, 3Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 4Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 5Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, 6University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 7Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Carotid subclinical atherosclerosis is independently associated with incident…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology